Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease

Jongyoon Shinn, Juyeon Lee, Seon Ah Lee, Seon Ju Lee, Ah Hyun Choi, Jung Seo Kim, Su Jin Kim, Hyo Jin Kim, Cherin Lee, Yejin Kim, Joohyeon Kim, Jonghee Choi, Byungchae Jung, Taeho Kim, Hyeon Taek Nam, Hyungjun Kim, Yonghyun Lee

Research output: Contribution to journalReview articlepeer-review

Abstract

RNA interference (RNAi) therapies have significant potential for the treatment of inflammatory bowel diseases (IBD). Although administering small interfering RNA (siRNA) via an oral route is desirable, various hurdles including physicochemical, mucus, and cellular uptake barriers of the gastrointestinal tract (GIT) impede both the delivery of siRNA to the target site and the action of siRNA drugs at the target site. In this review, we first discuss various physicochemical and biological barriers in the GI tract. Furthermore, we present recent strategies and the progress of oral siRNA delivery strategies to treat IBD. Finally, we consider the challenges faced in the use of these strategies and future directions of oral siRNA delivery strategies.

Original languageEnglish
Article number1969
JournalPharmaceutics
Volume14
Issue number9
DOIs
StatePublished - Sep 2022

Keywords

  • Immunotherapy
  • gene delivery
  • inflammatory bowel disease
  • nanomedicines
  • oral drug delivery
  • siRNA

Fingerprint

Dive into the research topics of 'Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this